Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Last Patient Last Visit for landmark Tourette Syndrome study

(Stockholm, 2 February 2023.) The Last Patient’s Last Visit took place on 1 February less than 12 months after the study’s initiation in Asarina Pharma’s Phase IIa clinical study in Sepranolone for the treatment of Tourette Syndrome. All patient examination and treatment in the study has now been completed and the patient dropout rate has…

Full PDF

Patient recruitment completed in landmark Tourette syndrome study

(Stockholm, 14 October 2022.) Asarina Pharma has completed the recruitment of patients to its Phase IIa clinical study in Tourette syndrome with a total of 28 patients enrolled and the last patient randomized on October 14. The dropout rate in the study remains unexpectedly low. Topline results are expected at the end of Q1 2023. The…

Full PDF

Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD

(Stockholm, 6 October 2022.) A new study in the journal Neurobiology of Stress reconfirms the central role the neurosteroid Allopregnanolone (ALLO) plays in stress-related conditions such as Tourette syndrome and OCD, and the efficacy of its endogenous modulator isoallopregnanolone in modulating its negative effects. This is the most extensive of four preclinical studies confirming these…

Full PDF

Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought

A new study by the U.S. CDC (Centers for Disease Control and Prevention) estimates that 1-in-50 children in the US may be affected by Tourette or persistent tic disorders, previous estimates were 1-in-100, and that up to 450,000 U.S. children and adults have Tourette. Asarina Pharma is currently carrying out a phase IIa clinical study into…

Full PDF

Asarina Pharma AB (publ) Q2 2022 Report released

CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second quarter of 2022. With more than two thirds of patients recruited and a drop-out rate of under 5%, the study remains fully funded, and we remain confident of reporting topline…

Full PDF
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...